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ABSTRACT 
  A large number of people have dementia all over the world, mainly suffering from Alzheimer's disease. The 
worldwide prevalence of dementia is expected to increase up to 24 million, and would to double every 20 years 
through to 2040, resulting in an expensive burden of disease.  The overlap between clinical groups and the 
longitudinal stability of the technique which currently may limit its clinical application in this context. The advent 
of new specific treatments for dementia will doubtless stimulate further research into the use of in vivo MRS as a 
clinical and scientific technique. Future technological developments may allow biochemical features of the 
underlying pathology in neurodegenerative disease.  
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1. INTRODUCTION  
More than 25 million people worldwide have dementia, mainly suffering from Alzheimer's disease (Wimo, 
2003). The worldwide prevalence of dementia is expected to increase up to 24 million, and would to double every 
20 years through to 2040, resulting in an expensive burden of disease.  Dementia is defined as a cluster of symptoms 
and signs characterized by difficulties in memory function, disorders in language and other functions, behavior 
changes, and problems in daily activities. Alzheimer's disease (AD) is the most common cause of dementia including 
about 75 % of all dementia cases, is known as a progressive neurodegenerative disorder. It has substantial impact on 
the patients, caregivers, and population (Wimo, 2003). Older age and genetic susceptibility are the main risk factors 
of AD. In addition, other potential risk factors and disorders would be cigarette smoking, high blood pressure and 
obesity, diabetes mellitus, and cerebrovascular lesions as well as psychosocial factors such as social activity, high 
level of education, somatic exercise, and mentally stimulating activity (Rasolabadi, 2015, Ghaffari, 2015). 
The age-standardized prevalence in people aged >65 years old is about 6.4 % for dementia and 4.4 % for 
AD (Berr, 2005). In the US, among people aged >70 years old the prevalence of AD is around 9.7 %.  The worldwide 
prevalence of dementia is about 3.9 % in people aged > 60 years, 1.6 % in Africa, 4.0 % in China and Western Pacific 
regions, 4.6 % in Latin America, 5.4 % in Western Europe, and 6.4 % in North America. The average incidence rate 
of AD among people aged >65 years in Europe was 19.4 per 1000 person-years. In the US was about 15.0 (male, 
13.0; female, 16.9) per 1000 person-years (Berr, 2005). 
There is a transitional, heterogeneous stage, mild cognitive impairment (MCI) with cognitive deficits beyond 
between physiological aging and dementia those expected based on the age and education of the individual, but 
which are not significant enough to interfere with their daily activities. 
Previous studies have demonstrated better understanding of the molecular pathogenesis of the hallmarks of 
AD such as plaques, composed of amyloid β (Aβ), and tangles, composed of hyperphosphorylated tau (Sturchler-
Pierrat, 1997). However, they have also emphasized on the pathogenic complexity of the disease. Early detection of 
AD and diagnosis at early stages of cognitive deficiency could result in the possibility of earlier therapeutic 
intervention and prevention of further progression of the disease.  
One of the neuroimaging methods that could be potentially useful for identification of patients with MCI 
who are at increased risk of developing dementia is magnetic resonance spectroscopy (1H-MRS). This method as a 
noninvasive method could provide information about metabolic changes in the brain tissue. It was reported that there 
are many differences in brain metabolism between demented elderly adults and unimpaired ones. However, various 
studies are obtained from different brain regions and with the application of different data acquisition and processing 
methods. Apart from studies comparing metabolites in healthy and cognitively impaired patients, there are just few 
conflicting studies that prospectively assessed 1H-MRS as a predictor of conversion of MCI to dementia. With an 
aging population that is getting increasingly older, the prevalence of dementia is increasing. Unfortunately, the 
diagnosis of dementia is typically made at a stage in which the underlying pathology has reached an advanced and 
irreversible state. In the past few years, MIC has been known as an early stage on the path towards dementia due to 
its important for predicting the progress of dementia at early stage, which it can still be treated, thereby stopping or 
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at least delaying the progression to dementia. The criteria for the diagnosis of MCI, however, are still under active 
development. Neuroimaging studies are necessary for understanding the pathophysiology of this early stage of 
cognitive deterioration, as well as besides volumetric analyses of grey and white matter, based on Magnetic 
Resonance Imaging (MRI) scans, and functional MRI of brain activation differences, neuroimaging using proton 
magnetic resonance spectroscopy (MRS) can yield information regarding metabolite changes in the brain 
representing early degeneration (Fatehi, 2016c). The first time in 2009, Petersen et al reported the criteria for the 
diagnosis of MCI with aim of capturing the prodromal state of AD. These criteria include a memory complaint that 
is confirmed by an informant and is documented by appropriate testing. In addition, the subject should be normal in 
other cognitive domains, be unimpaired in daily living and not demented. However, observations showed that 
subjects that had memory complaints not only may attributed to AD but also can associated with other types of 
dementia or psychiatric ailments. In 2004, amnestic MCI (aMCI) and non-amnestic MCI (naMCI) were added to the 
criteria, which memory impairments can be determined by impairments in either a single domain or multiple domains 
accounting for diverse etiologies. Reports of prevalence of MCI is highly variable, which can be in the range 3 to 
42%, with an increasing frequency observed from the age of 65 to 85 years (Mariani, 2007). The majority of the 
cases are of the amnestic type. This cohort of individuals has an annual conversion rate to AD of 3–17%, which is 
much higher than that for the general population (1–2%). However, the outcomes of MCI are not consistent. 
Although, most MCI patients progress to dementia, but some of them remain stable. So, these patients have 
impairments, but their disease does not progress to dementia. A small fraction may even improve to be categorized 
as no longer being impaired. Being a relatively new disorder, MCI continues to be characterized, with the diagnostic 
criteria being regularly updated to reflect the improved understanding of the disease. An important drawback of the 
current criteria is that they capture a clinical syndrome and not the disease. Therefore, various definitions are 
generally used in the diagnosis of MCI individual studies. These results are in line with the use of MCI definition in 
turn affects meaningful interpretation of the outcomes from various studies (Mariani, 2007). This different may be 
considered as an important reason for the variable results in epidemiological studies. So, standard criteria are 
necessary for diagnosing MCI (Ward, 2012). As the burden of AD is projected to increase in the near future, the 
interest in MCI as a predictor has also increased manifold. Research on biomarkers, such as brain abnormalities, can 
ultimately benefit reliability and early identification of the condition (Rahmani Tanha, 2016, Fatehi, 2016a). In 
addition, MCIneural basis studies can be useful in the necessary knowledge for developing evidence-based. In order 
to study the existence a consistent pattern or consolidate and highlight changes in MCI (Ward, 2012), we performed 
a meta-analysis. A main objective was to determine the changes of the most common metabolite as well as typical 
regional differences in MCI. 
Neuroimaging modalities: In studies with preclinical models, there are some limitations due to the inability to 
longitudinally collect anatomic and functional information. Some semi-invasive imaging methods can provide details 
with high spatial resolution such 2-photon microscopy. In contrast they are limited by a depth resolution of several 
hundred microns. Despite the high sensitivity in bioluminescent imaging, it is accompanied by a very poor spatial 
resolution. MRI is a very attractive noninvasive imaging modality that offers a spatial resolution of tens of microns, 
can be conducted longitudinally within the same subject, does not rely on ionizing radiation and exhibits clear 
advantages over other imaging methodologies such as PET or x-rays. Images are obtained in a short time and could 
provide outstanding anatomic and functional insights into pathologic processes. MRI was known as an important 
method in diagnose, monitor progression and responses to therapeutic regimes in individuals afflicted with AD 
(Mizuno, 2005). In MRI in AD, the main goals include developing novel imaging strategies and using existing 
strategies to monitor responses to therapies. There are 3 main areas where MRI is an invaluable tool in imaging AD 
models and patients. These include: (1) anatomic imaging, (2) imaging function/physiological processes, and (3) 
molecular imaging. Due the capability of MRI in exhibiting outstanding soft tissue contrast, it are generally applied 
for monitoring changes in brain anatomy during the development of AD and during responses to treatments. Through 
MRI, it is possible to detect and score gross anatomic changes in brain matter over time. For example Ferreira et al. 
studied assessing brain shrinkage over time in 6 individuals with AD treated with encapsulated nerve growth factor. 
In this study, the group used imaging data from the ADNI database that were age-matched and also Mini Mental 
Status (Mizuno, 2005). 
DTI: A complementary type of MRI for general anatomic MRI is that of DTI. DTI is an elegant MRI methodology 
that allows for the mapping of water diffusion in biological tissues and can be used to assess changes in white matter 
integrity. Subcellular constituents that can alter water diffusion patterns typically hinder the molecular diffusion of 
water. DTI builds on the basic principles of diffusion imaging and in this method, case each voxel indicates the rate 
of diffusion and the directionality of the diffusion in 3-dimensional space. The multiple diffusion-weighted 
acquisitions (giving directionality) and integrity of the associated white matter tracts (in the central nervous system) 
can be used in the calculation of a tensor (Gharib Salehi, 2016). DTI is a promising very powerful method in as 
sessing not only overt but also subtle perturbations in neuronal circuitry. One of the major readouts in DTI imaging 
ISSN: 0974-2115 
www.jchps.com                                                                    Journal of Chemical and Pharmaceutical Sciences 
October - December 2016 2709 JCPS Volume 9 Issue 4 
is that of fractional anisotropy (FA). Typically, FA is represented in a map of the brain but can also be quantified. 
The values of FA varies in the range 0 to 1, which the values close to 0 indicates a state of unrestricted diffusion of 
water (disordered system). While, the values close to 1 indicates restricted diffusion of water that is indicative of a 
very ordered system (such as along an intact axon). There are contradictory reports about white matter tractography 
perturbations in AD. It was reported that DTI can be applied to discriminate dementia Lewy bodies from AD, as with 
Firbank, 2007, finding greater mean diffusivity in AD than dementia with Lewy bodies in small regions in the left 
parietal and temporal lobe. Other groups have reported widespread perturbations in white matter connectivity. 
Recently, according to previous literature, certain areas of the white matter are affected in early onset AD including 
the parietal sector of the corpus callosum and the parahipoccampal cingulum (Wozniak, 2007). 
fMRI: Another type of MRI known as functional MRI (fMRI) typically refers to the monitoring of changes in blood 
flow in response to changes in neuronal activity. Quite commonly, blood oxygen level detection (BOLD) imaging is 
used in fMRI studies. Increased blood flow has been correlated with increases in neuronal activation, reflective of 
local field potentials. BOLD relies on changes in blood flow, blood volume, and the oxygenation state of blood to 
alter the MRI signal. Fast imaging sequences such as echoplanar imaging or fast gradient echo imaging sequences is 
used in BOLD fMRI studies. Resting state fMRI reflects not only functional information but also connectivity 
duringa ‘‘resting state,’’ which is when the subject is not asked to perform a specific task during the collection of the 
fMRI data. Brain regions that exhibit synchronous activity allow for the creation of functional maps and deviations 
from these functional networks can be evaluated in different disease states. For example, some resting state fMRI 
studies have recently shown that there are impairments in functional connectivity in the parahippocampal gyrus and 
that disruptions in the functional connectivity in the parahippocampal gyrus appeared to be associated with the 
severity of AD. Furthermore, some studies on resting state fMRI reported that there are many differences in distinct 
functional brain connectivity between AD and frontotemporal dementia. In term of analytical, brain network maps 
were used for evaluating changes in brain connectivity in AD patients through fMRI. They were able to discriminate 
between different stages of dementia those eventually lead to different impairments in brain connectivity. Its potential 
in the detection of changes in early stages of dementia in patients without severe or even mild clinical symptoms is 
noteworthy. It should also be noted that perturbations in blood flow have been reported in AD. Because of this, fMRI 
studies on blood flow changes as part of the readout should be carefully interpreted as well as  studies with animal 
models. For not only concerns regarding blood flow deficits but with the additional compounding factors that are 
introduced by anesthesia used during small animal imaging. Anesthesia is attributed to the additional factors of 
depressing neuronal activity and hemodynamic response affected by blood gas levels and hence the fMRI readout 
(Vernooij, 2007; Friston, 1998). 
MRS: MRS is a novel technique that provides a detailed picture of the in vivo biochemistry of the brain. Standard 
MRI scanner is used to present the spectrum reflecting the concentration of metabolites in the brain. Unfortunately, 
there are only a few metabolites in sufficient concentrations in the brain that be detected by MRI scanners, which 
was approved for safe use in humans. The detection of the metabolites is partly dependent on the strength of the 
field, with higher field strengths required to detect metabolites present in low concentrations. The metabolites that 
are present in high concentrations and thus most commonly studied are N-Acetyl Aspartate (NAA), choline (Cho), 
creatine (Cr), myo-inositol (mI), and glutamate and glutamine (Glx). Each of these metabolites is sensitive to a 
different pathological process in the brain. NAA is produced only within neurons and its concentration represents 
the neuronal density and viability. The peak on the spectra at 2.0 ppm is associated to the NAA. The presence of free 
glycerol phosphocholine and phosphocholin contribute to the choline signal. When these compounds constitute the 
cellular membrane are immobile. While, they become mobile, when the cell membrane has broken down and 
contribute to the Cho signal. A peak at 3.2 ppm is attributed to the Cho signal that is a marker for membrane integrity. 
Creatine and phosphocreatine were known as markers for energy metabolism which they have a peak at 3.03 ppm. 
It is supposed that Cr concentrations are fairly constant and is used as a reference value. Though, there are various 
reports disputing this claim. Myo-inositol as an osmolyte has a key role in the second messenger system. Its peak are 
appeared at 3.55 ppm, which can considered as a marker for glial activation. Glutamate and glutamine (Glx), key 
amino acids in the brain, appear as a single peak at 2.1–2.3 ppm in the spectrum. The peak can be resolved into 
individual wavelets in high-field MRI or less accurately by post-processing methods. A second smaller peak is also 
seen at 3.75 ppm provide a recent review on MRS. Magnetic resonance spectroscopy has many advantages. The 
MRS spectrum is easily obtained from a conventional MRI machine requiring relatively little time. It is possible to 
obtain spectrum either from a single voxel (SV) of interest or from multiple areas (Multivoxel Spectroscopy (MVS)) 
simultaneously making it sensitive to regional changes in metabolites. It is non-invasive and free from radiation 
which allows for monitoring the disease progression in patients. A number of studies have also studied the efficacy 
of pharmacological interventions using MRS. When combined with MRI it enhances the sensitivity and specificity 
of differentiating MCI from healthy subjects and from AD patients. In recent years, several studies on MCI conducted 
using different methods have shown metabolite profiles, which their profiles are similar to those typically found in 
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AD. Diverse regions of the brain have been studied with the posterior cingulate and the hippocampal regions 
receiving the most interest. Also the posterior white matter and gray matter, temporo-parietal region, prefrontal, 
medial temporal lobe, as well as the whole brain have been investigated. In comparison to control group, MCI 
patients have shown decreased NAA/Cr and Glx/Cr levels, and elevated mI/Cr and Cho/Cr levels, although some 
studies failed to find any differences between the groups. Only a few studies examined longitudinal changes in MCI 
subjects. Despite the difference in aims and methods used by the mentioned studies, their results conclude the 
potential of MRS as a diagnostic tool. Additional approaches have been used that incorporate the use of MRI contrast 
agents to target plaques. Reduced levels of N-acetyl aspartate (NAA) and elevated myo-inositol (mI) in the posterior 
cingulate region of subjects with probable AD were first reported from short echo time (TE) single voxel studies in 
the early 1990s. Since There so many MRS studies in AD using single voxel and CSI methods, the latter 
predominantly at long TE. These have allowed regional metabolite abnormalities in AD to be investigated. The most 
consistent finding is of reduced NAA and elevated mI, reflected in both metabolite ratios to Cr and absolute 
concentrations. MRS studies provide valuable information about regional distribution of changes in metabolite levels 
and as a result can avoid the potential problems with sampling errors that may occur with single voxel techniques. 
NAA, Cho and Cr are the metabolites most commonly mapped by MRS. Schuff et al. demonstrated decreased levels 
of NAA in the mesial temporal lobes, including the hippocampus and parietal grey matter but not in the frontal lobes 
or white matter, which agreed with the known distribution of the pathological changes in AD (Ferreira, 2011, Rumsey 
and Ernst, 2000). 
2. CONCLUSION 
Currently, AD diagnosis is a key factor in the treatment of disease which by improving medical imaging 
technology, new possibilities will be present for the evaluation of this disease at the structural, functional and cellular 
levels. New advanced MRI techniques such as DTI, fMRI, and MRS could have the ability of the assessment of 
cellular and functional, considering the fact that MRS has a more practical and validity role than the other techniques 
for clinicians. MRS may reveal quantitative abnormalities in normally occurring brain metabolites in patients with 
dementia. Of those which are currently accessible to clinical MRS, NAA and mI seem to be the most robust 
discriminators for the diagnosis and characterization of dementias. The combination of decreased NAA and elevated 
mI in the posterior cingulate region may be helpful in the diagnosis of AD, and may be used as an adjunct to structural 
imaging in a clinical environment. 
These metabolite abnormalities are likely to reflect the final common pathways of neuronal loss or 
dysfunction and gliosis, respectively. In addition, the anatomical and temporal patterns of metabolite abnormalities 
could help to distinguish different forms of dementing illness. Furthermore, metabolite abnormalities in those with 
mild cognitive impairment suggest a role for identifying those at risk of developing AD, and serial metabolite 
measurements may provide potential surrogates of disease progression and therapeutic response.  
The overlap between clinical groups and the longitudinal stability of the technique which currently may limit 
its clinical application in this context. The advent of new specific treatments for dementia will doubtless stimulate 
further research into the use of in vivo MRS as a clinical and scientific technique. Future technological developments 
may allow biochemical features of the underlying pathology in neurodegenerative disease.  
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